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Summary
Background The standard busulfan–cyclophosphamide myeloablative conditioning regimen is associated with 
substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing 
allogeneic stem-cell transplantation. Because the combination of busulfan plus ﬂ udarabine has been proposed to 
reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a 
preparative regimen in these patients.
Methods We did an open-label, multicentre, randomised, phase 3 trial for patients with acute myeloid leukaemia at 
25 hospital transplant centres in Italy and one in Israel. Eligible patients were aged 40–65 years, had an Eastern Cooperative 
Oncology Group performance status less than 3, and were in complete remission. Patients were randomly assigned 1:1 to 
receive intravenous busulfan plus cyclophosphamide or busulfan plus ﬂ udarabine. Treatment allocations were not 
masked to investigators or patients. Randomisation was done centrally via a dedicated web-based system using remote 
data entry, with patients stratiﬁ ed by donor type and complete remission status. Patients allocated to busulfan plus 
cyclophosphamide received intravenous busulfan 0∙8 mg/kg four times per day during 2 h infusions for four consecutive 
days (16 doses from days –9 through –6; total dose 12∙8 mg/kg) and cyclophosphamide at 60 mg/kg per day for two 
consecutive days (on days –4 and –3; total dose 120 mg/kg). Patients allocated to busulfan plus ﬂ udarabine received the 
same dose of intravenous busulfan (from days –6 through –3) and ﬂ udarabine at 40 mg/m² per day for four consecutive 
days (from days –6 through –3; total dose 160 mg/m²). The primary endpoint was 1-year non-relapse mortality, which was 
assessed on an intention-to-treat basis; safety outcomes were assessed in the per-protocol population. This trial has been 
completed and is registered with ClinicalTrials.gov, number NCT01191957.
Findings Between Jan 3, 2008, and Dec 20, 2012, we enrolled and randomly assigned 252 patients to receive busulfan 
plus cyclophosphamide (n=125) or busulfan plus ﬂ udarabine (n=127). Median follow-up was 27∙5 months 
(IQR 9∙8–44∙3). 1-year non-relapse mortality was 17·2% (95% CI 11∙6–25∙4) in the busulfan plus cyclophosphamide 
group and 7·9% (4∙3–14∙3) in the busulfan plus ﬂ udarabine group (Gray’s test p=0∙026). The most frequently 
reported grade 3 or higher adverse events were gastrointestinal events (28 [23%] of 121 patients in the busulfan plus 
cyclophosphamide group and 26 [21%] of 124 patients in the busulfan plus ﬂ udarabine group) and infections (21 [17%] 
patients in the busulfan plus cyclophosphamide group and 13 [10%] patients in the busulfan plus ﬂ udarabine group 
had at least one such event).
Interpretation In older patients with acute myeloid leukaemia, the myeloablative busulfan plus ﬂ udarabine 
conditioning regimen is associated with lower transplant-related mortality than busulfan plus cyclophosphamide, but 
retains potent antileukaemic activity. Accordingly, this regimen should be regarded as standard of care during the 
planning of allogeneic transplants for such patients.
Funding Agenzia Italiana del Farmaco.
Lancet Oncol 2015
Published Online
September 29, 2015
http://dx.doi.org/10.1016/
S1470-2045(15)00200-4
Hematology and Bone Marrow 
Transplant Unit, Azienda 
Ospedaliera Papa Giovanni 
XXIII, Bergamo, Italy 
(A Rambaldi MD, A Grassi MD, 
C Boschini MSc, M C Micò MD, 
E Oldani BiolSc); Fondazione 
Mario Negri Sud, Santa Maria 
Imbaro, Italy (A Masciulli MSc, 
R M Marﬁ si MSc); Bone Marrow 
Transplant Unit, University of 
Torino, Turin, Italy (A Busca MD, 
B Bruno MD); Hematology and 
Bone Marrow Transplant Unit, 
Ospedale Centrale di Bolzano, 
Bolzano, Italy (I Cavattoni MD); 
Bone Marrow Transplant 
Center, Ospedale Spirito Santo, 
Pescara, Italy (S Santarone MD); 
Hematology and Bone Marrow 
Transplant Unit, Ospedale 
San Bortolo, Vicenza, Italy 
(R Raimondi MD); Hematology, 
Azienda Ospedali Riuniti, 
Ancona, Italy 
(M Montanari MD); Hematology 
and Bone Marrow Transplant 
Unit, Azienda Policlinico-
Vittorio Emanuele, Catania, 
Italy (G Milone MD); Unit of 
Hematology, Policlinico 
Universitario A Gemelli, Rome, 
Italy (P Chiusolo MD); 
Department of Emergency and 
Organ Transplantation, Section 
of Hematology with 
Transplantation, Medical 
School, University of Bari, Bari, 
Italy (D Pastore MD); 
Department of Hematology, 
Bone Marrow Transplant Unit, 
University of Firenze, Florence, 
Italy (S Guidi MD, 
Prof A Bosi MD); Hematology 
Introduction
Allogeneic stem-cell transplantation is the most eﬀ ective 
way to control leukaemia relapse for patients with acute 
myeloid leukaemia. In younger adults (ie, aged 
18–40 years) with intermediate-risk or poor-risk acute 
myeloid leukaemia, allogeneic stem-cell transplant after 
myeloablative conditioning should be regarded as the 
treatment of choice for patients in their ﬁ rst complete 
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remission.1 Whether selection of transplant candidates 
can be improved by prediction of non-relapse mortality 
remains an issue under active investigation.2,3 In younger 
patients (ie, aged 18–40 years) the combination of a 
myeloablative dose of intravenous busulfan with 
cyclophosphamide is a standard preparative regimen, 
which compares favourably with the combination of 
cyclophosphamide and ablative doses (usually 12 Gy) of 
total body irradiation.4–6 However, myeloablative regimens 
are associated with substantial treatment-related toxicity 
in patients older than 40 years. In the HOVON-SAKK 
meta-analysis of several donor versus no donor studies,7 
no advantage was detected for patients older than 
40 years compared with younger patients.7 In the late 
1990s, non-relapse mortality in older patients was the 
major driver for the development of reduced intensity 
conditioning (RIC) regimens, which aimed to minimise 
regimen-related toxicity while securing engraftment and 
providing a platform for the graft-versus-leukaemia 
eﬀ ect.8,9 During the past two decades, the proportion of 
allogeneic grafts performed after RIC regimens has 
grown rapidly, resulting in a substantial rise in the 
median age of patients undergoing transplantation. 
However, after this initial enthusiasm, it was reported 
that RIC regimens were associated with a signiﬁ cantly 
increased risk of relapse.10 Overall, the beneﬁ t of reduced 
non-relapse mortality that RIC regimens provide is 
counterbalanced by an increased risk of relapse.11
Conditioning regimens need to be developed that will 
retain the antileukaemic activity of myeloablative 
conditioning, while reducing the transplant-related 
toxicity to the level of reduced RIC regimens: these 
programmes are tentatively referred to as reduced toxicity 
regimens.12 One such regimen is based on the 
combination of a myeloablative dose of intravenous 
busulfan (12∙8 mg/kg or equivalent) with ﬂ udarabine 
(160 mg/m² or similar), which has been reported to be 
eﬀ ective for patients with acute myeloid leukaemia.13 In a 
retrospective analysis,14 the busulfan plus ﬂ udarabine 
regimen was associated with reduced non-relapse 
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Panel: Research in context
Evidence before this study
We searched PubMed for articles that were published in English 
before June 1, 2015, and about conditioning regimens for 
allogeneic haemopoietic cell transplantation in acute myeloid 
leukaemia using the keywords “acute myeloid leukemia (AML)”, 
“allogeneic transplantation”, and “conditioning regimen”. In 
younger adults with intermediate or poor-risk acute myeloid 
leukaemia, allogeneic stem-cell transplant following 
myeloablative conditioning is the consolidation treatment of 
choice for patients in remission. Before we started our trial, the 
HOVON-SAKK meta-analysis of several donor versus no donor 
studies indicated no survival advantage for patients with acute 
myeloid leukaemia who had a donor but were aged older than 
40 years compared with younger patients. With the intent to 
reduce the high non-relapse mortality, which represents the 
major reason for transplant failure, several reduced intensity 
conditioning regimens have been proposed to minimise 
transplant toxicity. Although the feasibility of transplants in older 
patients using these programmes has been conﬁ rmed by many 
phase 2 studies, concerns have been raised about a signiﬁ cantly 
increased risk of relapse. At the time we designed our study, no 
abstracts or manuscripts had been reported with results from 
randomised trials comparing myeloablative with reduced 
intensity or reduced toxicity conditioning regimens in patients 
with acute myeloid leukaemia. For this reason we planned a 
randomised comparison between the standard myeloablative 
programme based on intravenous busulfan and 
cyclophosphamide and a reduced toxicity regimen based on the 
same myeloablative dose of busulfan and ﬂ udarabine. The latter 
regimen has been proposed to be similarly eﬀ ective to busulfan 
plus cyclophosphamide, with a remarkably good toxicity proﬁ le, 
low non-relapse mortality, and a low relapse rate in older patients 
with acute myeloid leukaemia.
Added value of this study
Two randomised trials comparing the same conditioning 
regimens in younger patients have been reported and 
provided conﬂ icting results regarding the eﬃ  cacy and toxicity 
of busulfan plus ﬂ udarabine. Additionally, a randomised trial 
(prematurely stopped because of slow accrual of patients) to 
compare reduced intensity total body irradiation plus 
ﬂ udarabine with standard total body irradiation plus 
cyclophosphamide did not identify any signiﬁ cant diﬀ erence 
in terms of non-relapse mortality, relapse incidence, disease-
free survival, or overall survival in patients with acute myeloid 
leukaemia with a median age of 45 years. To our knowledge, 
our study is the ﬁ rst randomised trial speciﬁ cally designed to 
compare these regimens in older patients with acute myeloid 
leukaemia undergoing transplantation in their ﬁ rst or 
subsequent haematological remission with a related or 
unrelated donor. Non-relapse mortality was signiﬁ cantly 
reduced with the busulfan plus ﬂ udarabine regimen compared 
with the busulfan plus cyclophosphamide regimen in all 
subgroups independent of patient age and sex, donor type, 
and acute myeloid leukaemia risk biology (European Leukemia 
Network score). This is probably because of reduced organ 
toxicity in the busulfan plus ﬂ udarabine group. The reduced 
non-relapse mortality did not come at the cost of an increased 
incidence of relapse.
Implications of all the available evidence
In older patients with acute myeloid leukaemia, the reduced 
toxicity of busulfan plus ﬂ udarabine, although still myeloablative, 
conferred low transplant-related mortality while preserving 
potent antileukaemic activity. Accordingly, we recommend that it 
should be considered as a standard of care in the planning of an 
allogeneic transplant for such patients. 
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mortality, shortened time to engraftment, and reduced 
incidence of acute and chronic graft-versus-host disease 
compared with busulfan plus cyclophosphamide. An 
increased frequency of relapse with the busulfan plus 
ﬂ udarabine regimen has been noted in some,15 but not 
all, studies.14 However, all of these analyses have been 
retrospective, and whether the busulfan plus ﬂ udarabine 
regimen represents an improvement for patients with 
acute myeloid leukaemia is not clear. Two randomised 
trials investigating these conditioning regimens in 
younger patients have been reported. In the ﬁ rst,16 which 
was done in a patient population that included patients 
with acute myeloid leukaemia, acute lymphoblastic 
leukaemia, and other haematological malignancies, the 
busulfan plus ﬂ udarabine regimen did not prove to be a 
suitable replacement for busulfan plus cyclophosphamide 
because a higher incidence of relapse was noted in the 
busulfan plus ﬂ udarabine regimen compared with the 
busulfan plus cyclophosphamide regimen. Conversely, 
in another trial in young patients with acute myeloid 
leukaemia, the busulfan plus ﬂ udarabine regimen was 
reported to be associated with less toxicity than the 
busulfan plus cyclophosphamide regimen, but had 
similar antileukaemic activity.17
In view of this conﬂ icting evidence, we did a 
randomised trial to compare the standard myeloablative 
busulfan plus cyclophosphamide regimen with the 
reduced toxicity busulfan plus ﬂ udarabine regimen for 
older patients with acute myeloid leukaemia undergoing 
allogeneic stem-cell transplantation. 
Methods
Study design and participants
This study was an open-label, multicentre, randomised, 
phase 3 trial done in 25 hospital transplant centres in 
Italy and one in Israel (appendix), coordinated by the 
Gruppo Italiano Trapianto di Midollo Osseo e Terapie 
Cellulari (GITMO) network. Patients were eligible if they 
had a diagnosis of acute myeloid leukaemia, were in 
their ﬁ rst, second, or further complete haematological 
remission (as established by morphological assessment 
of the bone marrow), were aged 40–65 years, had an 
Eastern Cooperative Oncology Group performance status 
less than 3, and had an HLA-identical matched related or 
matched unrelated donor as deﬁ ned by molecular high-
resolution typing (four digits) of the HLA gene loci for 
class I (HLA-A, HLA-B, and HLA-C) and class II (DRB1). 
If no completely identical donor could be identiﬁ ed 
according to the minimal degree of matching established 
by the Italian Bone Marrow Donor Registry, one antigen 
or allele disparity (class I) or one allele disparity (class II) 
between the patient and donor was acceptable. Estimated 
survival of patients at enrolment was more than 
3 months. We excluded patients if they were in ﬁ rst 
complete remission with t(15;17)(q22;q12) or PML/RARα-
positive acute promyelocytic leukaemia, or t(8;21)
(q22;q22)-positive and inv(16) or t(16;16)(p13;q22)-positive 
acute myeloid leukaemia with white blood cell counts 
less than 20 × 10⁹ cells per L at diagnosis and additional 
adverse cytogenetic abnor malities. We also excluded 
previously transplanted patients and patients with 
uncontrolled infections or severe cardiovascular, renal, 
hepatic, pulmonary, or psychiatric disorders or any 
disorder that compromised the ability to give truly 
informed consent for participation in this study. Patients 
with another progressive malignant disease or a history 
of other malignancies within 2 years before study entry 
were also excluded. After assessment of complete 
remission, no additional chemotherapy could be given 
before the start of the conditioning regimen.
We did the study in accordance with the International 
Conference on Harmonization for Good Clinical Practice 
and the appropriate regulatory requirements. The study 
was approved by the ethics committees of the 
participating centres and all patients and donors provided 
written informed consent before inclusion. The trial 
protocol was in accordance with the Declaration of 
Helsinki and is available online.
Randomisation and masking
Patients were randomly assigned (1:1) with a stratiﬁ ed 
biased coin algorithm with a variable block size strategy 
to receive either the busulfan plus cyclophosphamide or 
the busulfan plus ﬂ udarabine conditioning regimen. 
Randomisation was centralised at the Fondazione Mario 
Negri Sud (Santa Maria Imbaro, Chieti, Italy) and was 
done via a dedicated web-based system with remote data 
entry. Patients were stratiﬁ ed by donor type (matched 
related donor vs matched unrelated donor) and remission 
For the full protocol see http://
www.gitmo.it/images/pdf/
AMLR2/ProtocolloAMLR2.pdf
252 patients assessed for eligibility
252 randomised
125 assigned to busulfan 
 plus cyclophosphamide
127 assigned to busulfan 
 plus ﬂudarabine
121 received intervention 124 received intervention
125 included in intention-
 to-treat analysis
127 included in intention-
 to-treat analysis
121 included in per-protocol
 analysis
124 included in per-protocol 
 analysis
3 did not receive allocated 
 intervention
 3 relapsed before 
  conditioning
4 did not receive allocated 
 intervention
 3 withdrew consent
 1 relapsed before conditioning 
Figure 1: Trial proﬁ le
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status (ﬁ rst complete remission vs second or further 
complete remission). Treatment allocations were not 
masked to the investigators, participants, those assessing 
outcomes, or those analysing the data.
Procedures
The standard treatment group received a myeloablative 
combination of intravenous busulfan (Laboratoires 
Pierre Fabre, Boulogne, France) 0∙8 mg/kg four times 
per day during 2 h infusions for four consecutive days 
(16 doses from day –9 through day –6; total dose of 
12∙8 mg/kg) with cyclophosphamide 60 mg/kg per day 
for two consecutive days (on days –4 and –3; total dose of 
120 mg/kg). The experimental group received the same 
myeloablative dose of intravenous busulfan (from day –6 
through day –3) combined with ﬂ udarabine 40 mg/m² 
per day for four consecutive days (from day –6 through 
day –3) for a total dose of 160 mg/m². All patients received 
ﬁ xed doses of busulfan and no pharmacokinetic 
monitoring was done. No dose reductions or inter-
ruptions were allowed. On day 0, patients received either 
bone marrow cells or granulocyte-colony stimulating 
factor (G-CSF)-mobilised peripheral blood progenitor 
cells in their transplantation.
Prophylaxis for graft-versus-host disease was based on 
conventional ciclosporin A 1∙5 mg/kg twice per day by 
short intravenous infusion starting on day –1 before 
transplant (to reach target trough level concentration 
200 ng/mL or higher) and methotrexate 15 mg/m² given 
intravenously on day 1, and subsequently at 10 mg/m² 
intravenously on days 3, 6, and 11. Patients in both 
treatment groups who received stem cells from unrelated 
donors were treated with anti-thymocyte immuno-
globulin (Genzyme, Cambridge, MA, USA) 0∙5 mg/kg 
intravenously on day –3 and 2∙0 mg/kg intravenously on 
day –2 and, if the donor was identical, 2∙5 mg/kg on 
day –1. In cases with one antigen or allele disparity 
(class I) or one allele disparity (class II) between donor 
and recipient, the total dose of anti-thymocyte 
immunoglobulin could be increased up to 7∙5 mg/kg.
After transplantation, patients were followed up until 
the end of the study. The main outcome data were 
collected and the main assessments of adverse events 
were done on days 30, 60, 100, and 180, then at 1 year 
and 2 years after transplant and once per year thereafter. 
At the same timepoints, the ratio of donor-derived cells 
to recipient-derived bone marrow cells, peripheral blood 
cells, and T lymphocytes (chimerism) was evaluated by 
molecular analysis of short tandem repeats on DNA 
isolated from bone marrow and peripheral blood 
mononuclear cells. The analysis of the chimeric status 
of peripheral blood T lymphocytes was done after 
positive selection of CD3-positive cells sorted by the 
AutoMacs device (Miltenyi Biotec, Bergisch Gladbach, 
Germany). The achievement of a full haemopoietic 
donor chimerism (deﬁ ned as more than 95% of cells 
being of donor origin) was evaluated on bone marrow 
cells, peripheral blood cells and T lymphocytes at 30, 60, 
100, 180 days and 1 year after trans plant. Acute graft-
versus-host disease with organ involvement and 
symptoms was assessed on a weekly basis for the ﬁ rst 
3 months after transplant and graded according to the 
Busulfan plus 
cyclophosphamide 
(n=125)
Busulfan plus 
ﬂ udarabine 
(n=127)
Sex
Male 69 (55%) 70 (55%)
Female 56 (45%) 57 (45%)
Age (years) 51 (46–55) 51 (47–57)
40–50 66 (53%) 62 (49%)
51–65 59 (47%) 65 (51%)
Type of acute myeloid leukaemia
De novo 102 (82%) 103 (81%)
Secondary 22 (18%) 24 (19%)
Unknown* 1 (<1%) 0 (0%)
Disease status at allogeneic stem-cell transplantation
First complete remission 105 (84%) 108 (85%)
Second or further complete 
remission
19 (15%) 18 (14%)
Unknown* 1 (<1%) 1 (<1%)
ELN risk
Good 14 (11%) 13 (10%)
Intermediate 1 61 (49%) 62 (49%)
Intermediate 2 23 (18%) 17 (13%)
Adverse 23 (18%) 32 (25%)
Unknown* 4 (3%) 3 (2%)
HCT-CI
0 69 (55%) 72 (57%)
1–2 41 (33%) 27 (21%)
≥3† 14 (11%) 28 (22%)
Unknown* 1 (<1%) 0 (0%)
Donor type
Related 56 (45%) 58 (46%)
Unrelated 69 (55%) 69 (54%)
Graft source
Bone marrow 41 (33%) 36 (28%)
Peripheral blood 80 (64%) 88 (69%)
Unknown* 4 (3%) 3 (2%)
Donor–recipient sex pair
Female to male 19 (15%) 23 (18%)
Other 105 (84%) 104 (82%)
Unknown* 1 (<1%) 0 (0%)
Recipient/donor CMV serology
Negative/negative 8 (6%) 12 (9%)
Negative/positive 10 (8%) 6 (5%)
Positive/negative 31 (25%) 37 (29%)
Positive/positive 75 (60%) 69 (54%)
Unknown 1 (<1%) 3 (2%)
Data are n (%) or median (IQR). ELN=European Leukemia Network. 
HCT-CI=Hematopoietic Cell Transplantation-Speciﬁ c Comorbidity Index.  
*Patients not undergoing allogeneic stem-cell transplantation.
Table 1: Baseline demographic and transplant characteristics 
Articles
www.thelancet.com/oncology   Published online September 29, 2015   http://dx.doi.org/10.1016/S1470-2045(15)00200-4 5
Glucksberg scale. Chronic graft-versus-host disease was 
assessed at each follow-up visit and classiﬁ ed as limited 
or extensive.
Outcomes
The primary endpoint was the cumulative incidence of 
non-relapse mortality, assessed at 1 year after 
transplantation. Non-relapse mortality was deﬁ ned as 
death from any cause not subsequent to relapse. 
Secondary endpoints for eﬃ  cacy and safety were 
cumulative incidence of relapse, leukaemia-free survival, 
and overall survival at 1 and 2 years after transplantation, 
neutrophil and platelet engraftment, haemopoietic 
chimerism, incidence of rejection and graft failures, 
incidence of acute and chronic graft-versus-host disease, 
and cumulative incidence of regimen-related toxic 
eﬀ ects, according to Bearman’s criteria,18 and are 
described further in the appendix. Deaths after relapse 
were categorised as caused by the disease irrespective of 
the proximate cause. Haematological relapse was 
deﬁ ned via cytological assessment of the bone marrow. 
Neutrophil engraftment was deﬁ ned as the number of 
days after transplantation taken to achieve an absolute 
neutrophil count of at least 0·5 × 10⁹ cells per L and 
platelet engraftment was deﬁ ned as the number of days 
to maintain an untransfused platelet count of at least 
20·0 × 10⁹ cells per L. Graft failure was deﬁ ned as the 
absence of donor cells in the bone marrow by day 30 
after transplant. Graft rejection was deﬁ ned as the 
absence of donor cells in the bone marrow by day 60 
after transplant following an initial haemopoietic 
chimerism. Adverse events were recorded in accordance 
with the Medical Dictionary for Regulatory Activities 
(MedDRA) version 10.0 code and graded with the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (CTCAE) version 3.0.
Statistical analysis
We calculated the necessary sample size by assuming 
that 1-year non-relapse mortality in the busulfan plus 
cyclophosphamide group would be 25% (range 16–50). 
To show a reduction in non-relapse mortality of 50% to 
12·5% (range 0–30) in the busulfan plus ﬂ udarabine 
group, 240 patients needed to be enrolled and randomly 
assigned (120 patients in each group) for a power of 80% 
(type II error 0∙2). We used a two-sided alpha-level 
probability of 0∙05 (type I error).
We used χ² tests or Fisher’s exact test to assess 
categorical variables. Non-relapse mortality and the 
incidence of relapse incidence were considered to be 
competing events and we assessed group diﬀ erences 
using the  Fine and Gray’s non-parametric test.19 We 
calculated leukaemia-free survival and overall survival 
using the Kaplan-Meier method and we made 
comparisons by the log-rank test using censored data. 
We assessed the eﬀ ect of treatment on non-relapse 
mortality and cumulative incidence of relapse at 1 year in 
prespeciﬁ ed subgroups by ﬁ tting a Cox model and 
calculating cause-speciﬁ c HRs and 95% CIs. We assessed 
the eﬀ ect of treatment on non-relapse mortality and 
cumulative incidence of relapse at 1 year in prespeciﬁ ed 
subgroups by ﬁ tting a Cox model and calculating HRs 
and 95% CIs. We did multivariable analyses at the 
two-tailed 5% signiﬁ cance level and calculated adjusted 
hazard ratios (HRs) and 95% CIs by ﬁ tting Cox models. 
Non-relapse mortality, cumulative incidence of relapse, 
leukaemia-free survival, and overall survival were 
analysed on an intention-to-treat basis. The subgroup 
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Figure 2: Cumulative incidence of non-relapse mortality (A) and cumulative incidence of relapse (B)
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analysis, multi variable analysis, and safety assessments 
were done in the per-protocol population. All reported 
p values are two-sided.
One interim analysis was done after half of the patients 
(n=120) had been accrued, mainly to assess severe 
adverse eﬀ ects, which could aﬀ ect the continuation of 
the trial, but also to provide a ﬁ rst eﬃ  cacy proﬁ le with an 
assessment of the adequacy of the sample size 
calculation. The numbers of treatment failures and 
serious adverse events were closely monitored by the 
Data Safety Monitoring Board for unexpected trends. 
All analyses were done with SAS version 9.3 and 
R version 3.1.2 software.
This trial is registered with ClinicalTrials.gov, number 
NCT01191957.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The Steering Committee delegated the 
Fondazione Mario Negri Sud as the core data 
management and statistical facility, which did the 
centralised data collection, Good Clinical Practice quality 
monitoring, and analysis of data. The corresponding 
author (AR) and AM, CB, EO, and RMM had full access 
to all the data in the study and AR had ﬁ nal responsibility 
for the decision to submit for publication.
Results
From Jan 3, 2008, to Dec 20, 2012, we enrolled 
252 patients and randomly assigned them to receive 
busulfan plus cyclophosphamide (n=125) or busulfan 
plus ﬂ udarabine (n=127). Four patients had a leukaemia 
relapse before conditioning (three died subsequently and 
one received a transplant outside the protocol) and three 
patients withdrew consent (ﬁ gure 1). The allocated 
treatment was delivered to 121 patients in the standard 
busulfan plus cyclophosphamide group and 124 in the 
experimental busulfan plus ﬂ udarabine group; patients 
in this per-protocol population were treated with no 
deviations from the scheduled time and dose 
administration deﬁ ned by the study protocol. The main 
Busulfan plus 
cyclophosphamide 
(n=121)
Busulfan 
plus 
ﬂ udarabine 
(n=124)
p value
Total mortality 50 (41%) 51 (41%) 0·98
Relapse death 27 (22%) 38 (31%) 0·14
Non-relapse death 23 (19%) 13 (10%) 0·060
Graft-versus-host 
disease
5 (4%) 3 (2%) 0·50
Infection 8 (7%) 7 (6%) 0·75
Viral 0 (0%) 2 (2%) 0·50
Bacterial 5 (4%) 2 (2%) 0·28
Fungal 3 (2%) 1 (<1%) 0·37
Unknown cause 0 (0%) 2 (2%) 0·50
Organ failure 9 (7%) 1 (<1%) 0·0095
Heart 2 (2%) 1 (<1%) 0·62
Lung 4 (3%) 0 (0%) 0·058
Gastrointestinal 1 (<1%) 0 (0%) 0·49
Multiple 2 (2%) 0 (0%) 0·24
Haemorrhage 1 (<1%) 1 (<1%) 1·00
Other 0 (0%) 1 (<1%) 1·00
Data are n (%) for per-protocol population. Comparisons between groups were 
done with χ² tests or Fisher’s exact test as appropriate. 
Table 2: Causes of death 
Busulfan plus ﬂudarabine
Busulfan plus cyclophosphamide
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Figure 3: Kaplan-Meier curves of leukaemia-free survival (A) and overall survival (B)
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clinical features were balanced between the groups 
(table 1). Fewer patients with a Hematopoietic Cell 
Transplantation-Speciﬁ c Comorbidity Index (HCT-CI) 
score20 of 1–2, and more patients with a score of 3 or more, 
were allocated to the busulfan plus ﬂ udarabine group 
than to the busulfan plus cyclophosphamide group.
Median follow-up was 27∙5 months (IQR 9∙8–44∙3). At 
1 year, overall non-relapse mortality in the busulfan plus 
cyclophosphamide group was 17·2% (95% CI 11∙6–25∙4) 
compared with 7·9% (4∙3–14∙3) in the busulfan plus 
ﬂ udarabine group (Gray’s test p=0∙026; ﬁ gure 2). At 
1 year, non-relapse death occurred in 21 patients in the 
busulfan plus cyclophosphamide group and 10 patients 
in the busulfan plus ﬂ udarabine group. At 2 years, non-
relapse mortality in the busulfan plus cyclophosphamide 
group was 18·0% (12·3–26·4) versus 9·5% (5∙5–16∙3) in 
the busulfan plus ﬂ udarabine group, and at 5 years this 
was 19·0% (13·1–27·5) in the busulfan plus cyclo-
phosphamide group versus 10·6% (6·3–17·8) in the 
busulfan plus ﬂ udarabine group (Gray’s test p=0∙047 at 
2 years and p=0·050 at 5 years; ﬁ gure 2). At 1 year, the 
cumulative incidence of relapse was 22·1% (95% CI 
15∙8–30∙9) in the busulfan plus cyclophosphamide 
group and 25·2% (18∙6–34∙1) in the busulfan plus 
ﬂ udarabine group (Gray’s test p=0∙47; ﬁ gure 2). In both 
groups, the cumulative incidence of relapse remained 
similar at 2 years (29·6% [22·4–39·0] in the busulfan 
plus cyclophosphamide group vs 31·6% [24·4–40·9] in 
the busulfan plus ﬂ udarabine group; Gray’s test p=0∙59) 
and 5 years (38·1% [29·7–48·8] in the busulfan plus 
cyclophosphamide group vs 37·6% [29·7–47·4] in the 
busulfan plus ﬂ udarabine group; Gray’s test p=0∙70; 
ﬁ gure 2). All causes of death are reported in table 2.
Leukaemia-free survival for busulfan plus cyclo-
phosphamide versus busulfan plus ﬂ udarabine was 
60·7% (95% CI 52∙6–70) versus 66·9% (59∙2–75∙6) at 
1 year (p=0·38), 52·4% (44·3–62·1) versus 58·9% 
(50·9–68·2) at 2 years (p=0·36), and 42·9% (34·4–53·6) 
versus 51·8% (43·6–61·7) at 5 years (p=0·29; ﬁ gure 3). 
Relapses occurred in 43 patients in the busulfan plus 
cyclophosphamide group and in 46 patients in the 
busulfan plus ﬂ udarabine group. The proportion of 
patients who survived after relapse was signiﬁ cantly 
higher in the busulfan plus cyclo phosphamide group 
(16 [35%]) than in the busulfan plus ﬂ udarabine group 
(six [13%]; p=0·0083). Overall survival was similar 
between the busulfan plus cyclophosphamide group and 
the busulfan plus ﬂ udarabine group at 1 year (71·7% 
[64∙1–80∙2] vs 77·0% [70∙0–84∙7]; p=0·36), 2 years 
(64·2% [56·1–73·4] vs 62·4% [54∙5–71∙5]; p=0∙99]) and 
5 years (54·8% [45·5–66·0] vs 55·2% [46·7–65·4]; 
p=0·89; ﬁ gure 3). In our Kaplan Meier analysis, HR was 
0·83 (0·58–1·17) for leukaemia-free survival and 0·97 
(0·66–1·43) for overall survival.
Consistent with results in the intention-to-treat popu-
lation, in the per-protocol population, non-relapse 
mortality was improved for all subgroups of patients 
given busulfan plus ﬂ udarabine, compared with patients 
given busulfan plus cyclophosphamide, while subgroups 
of patients treated with either conditioning regimen had a 
similar cumulative incidence of relapse (ﬁ gure 4). The 
prognostic eﬀ ect of the conditioning regimen and all 
baseline characteristics on non-relapse mortality, 
cumulative incidence of relapse, leukaemia-free survival, 
and overall survival was assessed in the per-protocol 
population at 1 year after transplantation (table 3). By 
Favours busulfan plus
cyclophosphamide
Favours busulfan plus
ﬂudarabine
Busulfan plus
cyclophosphamide,
n (events)
Busulfan plus
fludarabine,
n (events)
p value
Non-relapse mortality
All patients
Sex
Male
Female
Age
<51 years
 ≥51 years
Disease status
First complete remission
Second or further remission
ELN risk
Good/Intermediate 1 
Intermediate 2/Adverse
HCT-CI 
0
1–2
≥3
Donor type
Related donor
Unrelated donor
Graft source
Bone marrow graft
Peripheral blood graft
Cumulative incidence of relapse
All patients
Sex
Male
Female
Age
<51 years
 ≥51 years
Disease status
First complete remission
Second or further remission
ELN risk
Good/Intermediate 1 
Intermediate 2/Adverse
HCT-CI 
0
1–2
≥3
Donor type
Related donor
Unrelated donor
Graft source
Bone marrow graft
Peripheral blood graft
121 (21)
 
 66 (13)
 55 (8)
 63 (8)
 58 (13)
102 (18)
 19 (3)
 
 75 (12)
 46 (9)
 
 67 (7)
 40 (9)
 14 (5)
 
 55 (8)
 66 (13)
 
 41 (8)
 80 (13)
121 (26)
 
 66 (13)
 55 (13)
 63 (16)
 58 (10)
102 (19)
 19 (7)
 
 75 (15)
 46 (11)
 
 67 (15)
 40 (8)
 14 (3)
 
 55 (12)
 66 (14)
 
 41 (12)
 80 (14)
124 (10)
 
 70 (6)
 54 (4)
 
 61 (4)
 63 (6)
107 (7)
 17 (3)
 
 75 (5)
 49 (5)
 
 71 (5)
 26 (3)
 27 (2)
 
 57 (2)
 67 (8)
 
 36 (4)
 88 (6)
124 (30)
 
 70 (21)
 54 (9)
 
 61 (16)
 63 (14)
107 (24)
 17 (6)
 
 75 (20)
 49 (10)
 
 71 (18)
 26 (6)
 27 (6)
 
 57 (12)
 67 (18)
 
 36 (7)
 88 (23)
0·46 (0·22–0·97)
0·44 (0·17–1·17)
0·49 (0·15–1·62)
0·51 (0·15–1·70)
0·42 (0·16–1·10)
0·37 (0·15–0·89)
1·04 (0·21–5·18)
0·43 (0·15–1·23)
0·49 (0·16–1·46)
0·71 (0·22–2·23)
0·48 (0·13–1·77)
0·17 (0·03–0·86)
0·24 (0·05–1·13)
0·60 (0·25–1·44)
0·53 (0·16–1·77)
0·43 (0·16–1·13)
1·09 (0·64–1·84)
1·52 (0·76–3·04)
0·65 (0·28–1·53)
1·01 (0·50–2·01)
1·23 (0·55–2·78)
1·19 (0·65–2·17)
0·87 (0·29–2·58)
1·37 (0·70–2·68)
0·72 (0·31–1·70)
1·18 (0·59–2·34)
1·02 (0·35–2·94)
0·91 (0·23–3·64)
0·93 (0·42–2·07)
1·23 (0·61–2·48)
0·58 (0·23–1·47)
1·52 (0·78–2·95)
0·042
0·10
0·24
0·27 
0·078
0·026
0·96
0·11
0·20
0·55
0·27
0·033
0·071
0·25
0·30
0·088
0·75
0·23
0·33
0·98
0·61
0·57
0·80
0·36
0·46
0·64
0·97
0·89
0·86
0·56
0·25
0·22
0·0
3
0·0
6
0·1
2
0·2
5
0·5
0
1·0
0
2·5
0
5·0
0
Figure 4: Non-relapse mortality and cumulative incidence of relapse at 1 year after transplantation
HRs and 95% CIs are calculated from Cox regression models. The dotted line represents the point estimated for 
non-relapse mortality and cumulative incidence of relapse for the per-protocol population. HR=hazard ratio. 
ELN=European Leukaemia Network. HCT-CI=Hematopoietic Cell Transplantation-Speciﬁ c Comorbidity Index.
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univariate analysis (data not shown) and multivariate 
analysis, disease status at transplant was the only factor 
that signiﬁ cantly aﬀ ected 1-year cumulative incidence of 
relapse, overall survival, and leukaemia-free survival, 
whereas the conditioning regimen was the only factor 
that signiﬁ cantly aﬀ ected non-relapse mortality at 1 year 
(table 3).
Median time to neutrophil engraftment was 16 days 
(IQR 14–18) in the busulfan plus cyclophosphamide 
group and 17 days (15–20) in the busulfan plus 
ﬂ udarabine group (Gray’s test p=0∙55). Median time to 
platelet engraftment was 20 days (15–25) for patients 
given busulfan plus cyclophosphamide and 17 days 
(14–21) for patients given busulfan plus ﬂ udarabine 
(Gray’s test p=0∙002; appendix). Two graft failures and 
two graft rejections occurred in patients receiving 
busulfan plus cyclophosphamide, whereas one graft 
rejection occurred in the busulfan plus ﬂ udarabine 
group. No diﬀ erence in haemopoietic chimerism existed 
between unfractionated mononuclear cells obtained 
from bone marrow and peripheral blood in either 
treatment group. However, when we compared the 
haemopoietic chimerism of puriﬁ ed peripheral blood 
T lymphocytes at early timepoints (days 30 and 60), full 
donor chimerism was signiﬁ cantly higher in the busulfan 
plus cyclophosphamide group (30/36 [83%] at 30 days; 
29/36 [81%] at 60 days) than in the busulfan plus 
ﬂ udarabine group (16/38 [42%] at 30 days, p=0·00026; 
23/40 [58%] at 60 days, p=0·031). A progressive increase 
in T-lymphocyte donor chimerism gradually developed at 
later timepoints in the busulfan plus ﬂ udarabine group, 
at days 100, 180, and 365 after transplantation (appendix). 
Despite the early delay in the achievement of full donor 
T lymphocyte chimerism in the busulfan plus ﬂ udarabine 
group, the number of donor lymphocyte infusions was 
not diﬀ erent between study groups (18 in the busulfan 
1-year non-relapse mortality 1-year cumulative incidence of relapse 1-year overall survival 1-year leukaemia-free survival
Events (%) HR (95% CI) p value Events (%) HR (95% CI) p value Events (%) HR (95% CI) p value Events (%) HR (95% CI) p value
Regimen
Busulfan plus 
cyclophosphamide 
(n=121)
21
(17%)
1·0 ·· 26
(21%) 
1·0 ·· 35
(29%)
1·0 ·· 47
(39%)
1·0 ··
Busulfan plus 
ﬂ udarabine (n=124)
10
(8%)
0·42
(0·19–0·91)
0·027 30
(24%)
1·09
(0·64–1·86)
0·75 27
(22%)
0·69
(0·41–1·15)
0·15 40
(32%)
0·79
(0·51–1·21)
0·28
Age (years)
<51 (n=124) 12
(10%)
1·0 ·· 32
(26%)
1·0 ·· 28
(23%)
1·0 ·· 44
(36%)
1·0 ··
≥51 (n=121) 19
(16%)
1·57
(0·76–3·26)
0·22 24
(20%)
0·81
(0·48–1·38)
0·44 34
(28%)
1·30
(0·79–2·16)
0·30 43
(36%)
1·03
(0·67–1·57)
0·91
Disease status at allogeneic stem-cell transplantation
First complete 
remission (n=209)
25
(12%)
1·0 ·· 43
(21%)
1·0 ·· 47
(23%)
1·0 ·· 68
(33%) 
1·0 ··
Second or further 
complete remission 
(n=36)
6
(17%)
1·46
(0·58–3·69)
0·42 13
(36%)
2·08
(1·07–4·02)
0·030 15
(42%)
1·91
(1·03–3·53)
0·039 19
(53%)
1·81
(1·06–3·09)
0·031
ELN risk
Good/intermediate 1 
(n=150)
17
(11%)
1·0 ·· 35
(23%)
1·0 ·· 39
(26%)
1·0 ·· 52
(35%)
1·0 ··
Intermediate 
2/adverse (n=95)
14
(15%)
1·32
(0·64–2·71)
0·46 21
(22%)
0·98
(0·56–1·70)
0·94 23
(24%)
0·99
(0·58–1·68)
0·96 35
(37%)
1·10
(0·71–1·70)
0·68
HCT-CI
0 (n=138) 12
(9%)
1·0 ·· 33
(24%)
1·0 ·· 30
(22%)
1·0 ·· 45
(33%)
1·0 ··
1–2 (n=66) 12
(18%)
1·76
(0·78–3·97)
0·17 14
(21%)
0·82
(0·43–1·56)
0·54 18
(27%)
1·13
(0·63–2·05)
0·68 26
(39%)
1·10
(0·67–1·79)
0·72
≥3 (n=41) 7
(17%)
2·25
(0·86–5·90)
0·10 9
(22%)
0·96
(0·45–2·03)
0·91 14
(34%)
1·72
(0·90–3·30)
0·10 16
(39%)
1·29
(0·72–2·31)
0·40
Donor type
Related (n=112) 10
(10%)
1·0 ·· 24
(21%)
1·0 ·· 22
(20%)
1·0 ·· 34
(30%)
1·0 ··
Unrelated (n=133) 21
(16%)
1·53
(0·71–3·34)
0·28 32
(24%)
1·09
(0·62–1·90)
0·76 40
(30%)
1·37
(0·80–2·35)
0·26 53
(40%)
1·21
(0·77–1·90)
0·40
Baseline characteristics that are not included in this table were analysed only in univariate analysis. HR=hazard ratio. ELN=European Leukemia Network. HCT-CI=Hematopoietic Cell Transplantation-Speciﬁ c 
Comorbidity Index.
Table 3: Prognostic factors for outcomes at 1 year after transplantation 
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plus cyclophosphamide group vs 14 in the busulfan plus 
ﬂ udarabine group, χ² p=0∙41).
At least one grade 3 or worse adverse event was 
reported for 62 (51%) of 121 patients in the busulfan 
plus cyclo phosphamide group and 46 (37%) of 
124 patients in the busulfan plus ﬂ udarabine group 
(table 4). The most frequently reported grade 3 or 
higher adverse events were gastrointestinal events 
(28 [23%] patients in the busulfan plus cyclo-
phosphamide group vs 26 [21%] patients in the busulfan 
plus ﬂ udarabine group) and infections (21 [17%] 
patients in the busulfan plus cyclophosphamide group 
and 13 [10%] patients in the busulfan plus ﬂ udarabine 
group had at least one such event). Adverse events with 
an outcome of death were reported for 19 (16%) patients 
in the busulfan plus cyclo phosphamide group and 10 
(8%) in the busulfan plus ﬂ udarabine group. Eight 
secondary malignancies were diagnosed in six patients, 
all of whom received busulfan plus ﬂ udarabine (table 4). 
The most common conditioning regimen-related toxic 
eﬀ ects assessed shortly (within 28 days) after 
transplantation are shown in table 5. Four patients (two 
in each treatment group) had a diagnosis of venous 
occlusive disease. The 100-day cumulative incidence of 
grade II–IV acute graft-versus-host disease was 28·1% 
(95% CI 21∙1–37∙4) in the busulfan plus 
cyclophosphamide group versus 19·4% (13∙5–27∙8) in 
the busulfan plus ﬂ udarabine group (Gray’s test 
p=0∙12), whereas grade III–IV acute graft-versus-host 
disease was signiﬁ cantly more common in the busulfan 
plus cyclo phosphamide group (12 [10%] patients) than 
in the busulfan plus ﬂ udarabine group (three [2%] 
patients; Gray’s test p=0∙014; appendix). At 1 year, the 
cumulative incidence of chronic graft-versus-host 
disease was 27·5% (20∙6–36∙9) in the busulfan plus 
cyclophosphamide group and 25·8% (19∙1–34∙8) in the 
busulfan plus ﬂ udarabine group.
Busulfan plus cyclophosphamide (n=121) Busulfan plus ﬂ udarabine (n=124)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Infection 58 (48%) 13 (11%) 4 (3%) 8 (7%) 43 (35%) 6 (5%) 0 7 (6%)
Gastrointestinal 27 (22%) 27 (22%) 0 1 (<1%) 19 (15%) 26 (21%) 0 0
Metabolic/laboratory 26 (21%) 8 (7%) 1 (<1%) 0 18 (15%) 2 (2%) 0 0
Pulmonary/upper respiratory 16 (13%) 8 (7%) 1 (<1%) 4 (3%) 7 (6%) 2 (2%) 1 (<1%) 0
Cardiac arrhythmia/cardiac general 10 (8%) 1 (<1%) 0 3 (2%) 8 (6%) 3 (2%) 0 0
Neurology 10 (8%) 3 (2%) 1 (<1%) 0 5 (4%) 1 (<1%) 0 0
Constitutional symptoms* 10 (8%) 1 (<1%) 0 0 3 (2%) 2 (2%) 0 0
Allergy/immunology 9 (7%) 1 (<1%) 0 0 2 (2%) 0 0 0
Blood/bone marrow 7 (6%) 13 (11%) 3 (2%) 0 7 (6%) 8 (6%) 1 (<1%) 1 (<1%)
Dermatology/skin 7 (6%) 1 (<1%) 0 0 5 (4%) 0 0 0
Renal/genitourinary 7 (6%) 3 (2%) 1 (<1%) 0 3 (2%) 0 0 0
Musculoskeletal/soft tissue 6 (5%) 3 (2%) 0 0 4 (3%) 0 0 0
Haemorrhage/bleeding 6 (5%) 2 (2%) 0 1 (<1%) 4 (3%) 0 0 1 (<1%)
Endocrine 5 (4%) 1 (<1%) 0 0 2 (2%) 1 (<1%) 0 0
Hepatobiliary/pancreas 2 (2%) 1 (<1%) 0 0 4 (3%) 1 (<1%) 0 0
Ocular/visual 2 (2%) 1 (<1%) 0 0 3 (2%) 1 (<1%) 0 0
Pain 2 (2%) 3 (2%) 0 0 1 (<1%) 0 0 0
Vascular 2 (2%) 2 (2%) 0 0 1 (<1%) 0 0 0
Coagulation 1 (<1%) 0 2 (2%) 0 0 0 0 0
Secondary malignancy 0 0 0 0 5 (4%) 3 (2%) 0 0
Multi-organ failure 0 0 0 2 (2%) 0 0 0 1 (<1%)
Data are number of patients (%). *Includes general symptoms of fever, fatigue, and insomnia. Only grade 1–2 adverse events that occurred in more than 10% of patients in 
any group are reported, whereas all grade 3, 4, and 5 adverse events that occurred after treatment allocation are reported.
Table 4: Adverse events 
Busulfan plus cyclophosphamide 
(n=121)
Busulfan plus ﬂ udarabine (n=124)
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
Mucosa 8 (7%) 23 (19%) 1 (<1%) 11 (9%) 23 (19%) 1 (<1%)
Liver 9 (7%) 5 (4%) 0 4 (3%) 1 (<1%) 1 (<1%)
Gut 7 (6%) 4 (3%) 2 (2%) 3 (2%) 1 (<1%) 0
Bladder 0 3 (2%) 2 (2%) 0 0 0
Heart 1 (<1%) 2 (2%) 1 (<1%) 1 (<1%) 0 0
Kidney 2 (2%) 0 0 2 (2%) 0 0
Central nervous system 0 1 (<1%) 1 (<1%) 0 2 (2%) 0
Lung 1 (<1%) 0 0 0 1 (<1%) 0
Data are number of patients (%). Toxic eﬀ ects were judged with Bearman’s criteria.18
Table 5: Regimen-related toxic eﬀ ects by organ system within 28 days after transplantation in the 
per-prot ocol population
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Discussion
In this study, the combination of busulfan plus 
ﬂ udarabine, compared with busulfan plus cyclo-
phosphamide, was associated with signiﬁ cantly lower 
non-relapse mortality for older (median age 51 years) 
patients with acute myeloid leukaemia who underwent 
allogeneic haemopoietic stem-cell transplant from an 
HLA-matched related or unrelated donor. Non-relapse 
mortality in patients receiving the busulfan plus 
ﬂ udarabine regimen was lower in all subgroups analysed 
compared with that for patients in the busulfan plus 
cyclophosphamide group, especially for patients in their 
ﬁ rst complete remission and in those with an HCT-CI of 
3 or greater, and was independent of patient age and sex, 
donor type, graft type, and acute myeloid leukaemia risk 
biology. Chemotherapy-related organ toxic eﬀ ects were 
less common in patients treated with the busulfan plus 
ﬂ udarabine regimen than those treated with the busulfan 
plus cyclophosphamide conditioning; the primary 
endpoint of the study was probably met because of the 
reduced organ toxicity of the busulfan plus ﬂ udarabine 
regimen. Fludarabine has been postulated to be associated 
with reduced toxic eﬀ ects in several organs, including the 
heart, lungs, and liver, while the myelo ablative dose of 
busulfan was predicted to preserve the antileukaemic 
eﬀ ect of the regimen. Most importantly, the reduced non-
relapse mortality did not come at the cost of a signiﬁ cantly 
increased incidence of relapse, which was similar 
between the busulfan plus ﬂ udarabine and busulfan plus 
cyclophosphamide groups, both overall and in subgroup 
analysis.
Our results concur with those reported in other clinical 
trials. In a phase 2 study,21 patients aged 50–70 years were 
given transplants for myeloid malignancies after a 
busulfan plus ﬂ udarabine myeloablative con ditioning 
regimen. For patients in complete remission at the time of 
the transplant, 1-year transplant-related mortality was 19%, 
with a 2-year event-free survival of 71% and an overall 
survival of 68%. Additionally, in a randomised clinical 
trial17 done in younger (median age of 30 years) patients 
with acute myeloid leukaemia, non-relapse mortality at 
5 years was lower in patients treated with busulfan plus 
ﬂ udarabine (10%) compared with those given busulfan 
plus cyclophosphamide (19%). As in our study, the overall 
incidence of relapse was superimposable between the 
study groups and, although not signiﬁ cant, the patients 
who received ﬂ udarabine had improved disease-free 
survival and overall survival compared with those who 
received cyclophosphamide.
The lower non-relapse mortality at 1 year in favour of 
the busulfan plus ﬂ udarabine group was maintained up 
to 5 years. Therefore, the reduction of the antileukaemic 
power of a conditioning regimen should be carefully 
assessed for patients with acute myeloid leukaemia up to 
the age of 65 years. Notably, the lower transplant-related 
mortality is not a consequence of poor performance in 
the control group. In fact, the busulfan plus 
cyclophosphamide regimen was better tolerated than 
initially postulated when the trial was designed and non-
relapse mortality in this group was similar to that 
reported in large international non-randomised studies4–6 
that were done in patients of similar or younger median 
age with myeloid malig nancies. The overall good 
performance of both treatment groups is emphasised by 
three further ﬁ ndings. First, most patients had 
intermediate-risk or high-risk acute myeloid leukaemia 
and only six patients with a favourable cytogenetic proﬁ le 
had received transplants in their ﬁ rst remission. In this 
respect, our results are similar to those reported in a 
comparable set of older patients with acute myeloid 
leukaemia who were enrolled into studies in the 
HOVON-SAKK analysis.22 Second, patients receiving 
transplants from related or unrelated donors were 
equally represented in both treatment groups and no 
diﬀ erence existed in the treatment outcome according to 
stem cell source or donor type. Our results also support 
the notion that transplantations from matched related 
donors and matched unrelated donors produce similar 
outcomes for patients with acute myeloid leukaemia.23 
All transplants from unrelated donors in our study 
included an intermediate dose of antithymocyte 
immuno globulin as part of the con ditioning regimen 
and this did not translate into any signiﬁ cant increase of 
relapse or transplant-related complications. Third, the 
incidence of venous occlusive disease was very low in 
both treatment arms: the reduction of this life-
threatening complication is probably related to the use of 
an intravenous formulation of busulfan.24 Importantly, 
after busulfan plus ﬂ udarabine was given to patients, the 
speed and robustness of haematological engraftment 
was similar to, if not better than, that observed in the 
control group, despite the fact that full T-cell engraftment 
was delayed. This ﬁ nding did not translate into an 
increase in early or late graft failures and we speculate 
that the signiﬁ cantly reduced incidence of grade III–IV 
acute graft-versus-host disease reported in the busulfan 
plus ﬂ udarabine group might be at least partly related to 
the kinetics of T-cell reconstitution in this group.
Several studies25–27 have reported that reduction of the 
myeloablative component of chemotherapy-based con-
ditioning regimens is associated with a signiﬁ cant increase 
in relapse incidence, although in a recent randomised 
trial,28 no diﬀ erence in relapse was detected in a comparison 
of total body irradiation-based conditioning regimens 
(8 Gy vs 12 Gy) for patients with acute myeloid leukaemia. 
A phase 3 study (ClinicalTrials.gov, number NCT01339910) 
by the Bone Marrow Transplant Clinical Trials network to 
compare myeloablative conditioning with reduced 
intensity conditioning in patients with acute myeloid 
leukaemia and myelodysplastic syndrome, aged 
18–65 years, was closed prematurely because of an excess 
of relapse in the reduced intensity programme.
Our results contrast with those published by Lee and 
colleagues16 who compared a busulfan plus ﬂ udarabine 
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conditioning regimen with busulfan plus cyclo -
phosphamide in 126 younger adults (median age 41 years) 
eligible for myeloablative conditioning. Although severe 
(grade 3 or higher) infection and gastrointestinal adverse 
events were signiﬁ cantly more common in the busulfan 
plus cyclophosphamide group, the frequency of hepatic 
adverse events was similar between the two groups. 
Moreover, overall non-relapse mortality was similar 
between the two groups and the busulfan plus 
cyclophosphamide group had improved 2-year overall 
survival and event-free survival compared with the 
busulfan plus ﬂ udarabine group. Beyond the substantial 
diﬀ erence in the median age of the patients in this study 
and ours, we must emphasise the fact that Lee and 
colleagues’ study had a smaller number of patients and 
seemed to lack a formal sample size calculation. 
Furthermore, only 70 of 126 patients in that study had a 
diagnosis of acute myeloid leukaemia.
Our study has several limitations that should be taken 
into consideration. Most patients were in their ﬁ rst 
complete remission and it is possible that before being 
randomly assigned to a myeloablative conditioning 
regimen they had been selected for enrolment on the 
basis of a favourable HCT-CI score and good 
performance status.29 Accordingly, the generalisability of 
our results should be critically assessed when decisions 
are made about the conditioning regimen for older 
patients with acute myeloid leukaemia, especially when 
severe comorbidities or poor perfor mance status are 
present. Additionally, we recognise that for patients who 
relapse after transplantation, the outcome was better in 
the busulfan plus cyclo phosphamide group than in the 
busulfan plus ﬂ udarabine group. The reduced success of 
the rescue treatment for disease relapse after busulfan 
plus ﬂ udarabine treatment might be a matter of chance, 
but alternative explanations include the possible 
selection of more aggressive leukaemic cell clones that 
have survived a purine analogue-containing chemo-
therapy and the increased incidence of infectious 
complications. Finally, although non-relapse mortality 
was lower in the busulfan plus ﬂ udarabine group than 
in the busulfan plus cyclophosphamide group, overall 
survival was not diﬀ erent between the groups, which 
emphasises the fact that leukaemia relapse after 
transplantation remains an unmet clinical need for 
patients with acute myeloid leukaemia. For this reason, 
innovative post-engraftment treatments with cells or 
drugs should now be regarded as an integral part of the 
allogeneic stem-cell transplantation platform, and 
clinical trials that have been appropriately designed to 
address the eﬃ  cacy and toxic eﬀ ects of such new 
approaches are needed.30
Our results support myeloablative busulfan plus 
ﬂ udarabine as a highly eﬀ ective conditioning regimen 
for patients aged 40–65 years with acute myeloid 
leukaemia, conferring lower transplant-related mortality 
than with standard treatment. These results might be 
useful in the planning of allogeneic transplants for older 
patients with acute myeloid leukaemia.
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